An FDA Nominee, Biologics Reviews Move to CDER

The FDA's recent announcement that the responsibility for reviewing biologics would be transferred from the Center for Biological Research (CBER) to the Center for Drug Evaluation and Research came amidst growing industry and congressional criticism about CBER's handling of Biologics Licensing Applications (BLAs). But the FDA's failure to spell out the details of the reorganization leaves many questions unanswered, among them: what will be the implications for biogenerics; how will CBER's funding be affected; and what will be the impact on pending BLAs?

Biotech companies have been fuming for some time about the handling of Biologics Licensing Applications (BLAs) by the FDA's Center for Biologics Research and Evaluation (CBER). The complaints include prolonged approval times (an average 19.6 months last year for BLAs versus 16.4 months for New Drug Applications reviewed by the Center for Drug Evaluation and Research (CDER)), as well as inconsistencies between the handling of approval applications by CBER and by CDER. A particular sore point concerns CBER's failure to employ Special Protocol Assessments (SPAs)—written contracts between sponsors and the FDA that, by including specifications regarding the design of pivotal studies, make it more difficult for the agency to change the rules midstream. In the five years since Congress authorized the use of SPAs, CDER has entered into more than 120 such agreements to CBER's one.

Indeed, Congress—probably the single most effective motivator for FDA change, good or bad—has made clear its dissatisfaction with the way...

More from Archive

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.